Drug Deposition in Lungs Using Gamma Scintigraphy


 
LRRI has a new nuclear imaging laboratory capable of conducting radiolabeled drug deposition studies in both animal and human subjects.
 

 

LRRI has a state-of-the-art nuclear imaging laboratory capable of conducting radiolabeled drug deposition and biodistribution studies. Studies can be conducted in all preclinical species as well as in humans.   Imaging modalities include SPECT, SPECT/CT, PET, CT, and MRI.  LRRI's team can assist with all areas of both clinical and preclinical studies including radiolabeling, study design, study execution, and complex data analysis.

Key Capabilities:

  • Full range of preclinical (mouse, rat, ferret, dog, and primate) and clinical imaging capabilities
  • SPECT and Planar gamma scintigraphy image acquisition
  • Whole organ image quantification and/or in-depth regional organ quantification
  • Complex data analysis to facilitate use of anatomical data sets from CT and/or MRI
  • Experience with radiolabeling and delivering nebulizers, dry powders, and metered dose inhalers
  • Support for a full range of isotopes including technetium-99m, iodine-131, xenon-133, etc.
  • Experienced laboratory personnel with a long history of conducting radiolabeled drug deposition studies

ACCESS LRRI PUBLICATIONS ON THIS TOPIC IN PUBMED

Publications

The following is a list of LRRI publications on drug deposition studies

  1. Leach, C. L., P. J. Kuehl, R. Chand, L. Ketai, J. P. Norenberg, and J. D. McDonald: Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann. Allergy Asthma Immunol. 108(3): 195-200, 2012
  2. Garcia, A., P. Mack, S. Williams, C. Fromen, T. Shen, J. Pillai, P. J. Kuehl, M. Napier, J. M. Desimon and B. W. Maynor: Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and other Pharmaceutical Applications. J. Drug Delivery. Article ID 941243, 2012.
  3. Kuehl, P. J., T. L. Anderson, G. Candelaria, B. Gershman, K. Harlin, J. Y. Hesterman, T. Holmes,  J. Hoppin, C. Lackas, J. P. Norenburg, H. Yu, J. D. McDonald:  Regional particle size dependent deposition of inhaled aerosols in rats and mice. Inhal Toxicol. 24(1):27-35, 2012.
  1. Kuehl, P. J.: Imaging Pulmonary Drug Delivery. In Controlled Pulmonary Drug Delivery (H.D.C. Smyth and A.J. Hickey eds), pp.475-487, Springer, New York, NY, 2011.
  2. Cheng, Y. S., H. Irshad, P. Kuehl, T. D. Holmes, R. Sherwood and C. H. Hobbs:  Lung Deposition of Droplet Aerosols in Monkeys.  Inhal. Toxicol. 20(11): 1029-1036, 2008.
  3. Leach, CL, Davidson, PJ, Hasselquist, BE, and Boudreau, RJ (2005). Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 18(4), 379-385.
  4. Leach, CL, Davidson, PJ, Hasselquist, BE, and Boudreau, RJ (2002). Lung deposition of HFA-Beclomethasone is greater than that of CFC-fluticasone and CFC-beclomethasone: A cross-over study in healthy volunteers. CHEST 122 (2) 510-516.
  5. Leach, CL (1999). Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J. Allergy Clin. Immunol. 104:S250-252.
  6. Leach, CL, Davidson, PJ, and Boudreau, RJ (1998). Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur. Res. J. 12, 1346-1353.
  7. Leach, CL (1998). Improved delivery of inhaled steroids to the large and small airways. Respir. Med. 92 (Supplement A), 3-8.
  8. Leach, CL (1998). Relevance of radiolabeled steroid inhalation studies to clinical outcomes. J. Aerosol Med. 11(1), S29-S34.